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Editorial
Are cytokine responses in renal cell cancer the product
of placebo effect of treatment or true biotherapy? What
trials are needed now?
RTD Oliver
School of Medicine & Dentistry, St Bartholomew's and The Royal London Hospitals, Department of Medical Oncology, West Smithfield,
London EClA 7BE, UK
Today, my longest surviving patient with complete remission from
single-agent interleukin 2 (IL-2) is alive and disease free 10 years
after he had presented 2 years post nephrectopy with lung metas-
tases and a renal bed recurrence (Leahy et al, 1992). This was
invading the spinal canal and inducing severe pain that was poorly
controlled even by high doses ofmorphine and had induced anaes-
thesia in the L2 dermatome. The fact that this patient was able to
stop morphine within 7 days of starting treatment provides added
credence to the reality ofthe response. Such observations make it
difficult to believe that there is not a subgroup of patients with
renal cell cancer that benefit from immune manipulation. This is
despite the publication in this issue ofyet another negative trial of
biological therapy to go with the three others presented at ASCO
this year. Once a true complete remission is achieved, relapse is
rare and the chance ofachieving such durable complete remission
is linked to a specific HLA antigen in the responder (Bain et al,
1997), adding support to the idea that immune response is rele-
vant. The debate today questions whether one achieves more
response by combination therapy and why, repeatedly, the
response rate to the same regimen has ranged so widely with initial
encouraging response in the 30-40% range being followed by
cummulative data indicating a 15-20% response (Oliver, 1994).
The question arises as to whether there are other factors involved.
Having attended rounds with Julian Bloom, whose response rate to
medroxyprogesterone (17%) was 12% higher than that now
reported (Bloom, 1973; Ritchie and Oliver, 1995) as well as with
Steve Rosenberg whose initial response rate to IL-2 plus LAK
cells (35%) was 12% higher than is now reported (Rosenberg et al,
1989; Whittington and Faulds, 1993), one has to accept either that
there is a major selection in referral patterns to specialist centres
or, having observed the powerful impact of these clinicians on
patients, that there might be a placebo effect of treatment as a
component of the response rate? Such concerns are the principal
reason why, despite undisputed better survival in randomized trials
after autologous lymphocyte therapy in both metastatic patients
(Osband et al, 1990) and high-risk disease patients after nephrec-
tomy (Sawczuk et al, 1997), there is scepticism in the scientific
community as to whether it is a placebo effect of the process or
whether the 6-weekly leucophoresis and retransfusing after in
vitro lycophocyte activation by culture with cytokine 'soup' actu-
ally does alter immune response to renal cancer. The fact that
survival correlates with IL-1 levels induced by the cytokine soup
(Osband et al, 1990) is the main observation that allows one to
believe that there might be a true immunological effect oftherapy.
In my own studies on spontaneous regression, the higher than
expected incidence ofevents when initially published [7% after 64
cases studied (Oliver et al, 1989) vs 4% after 200 cases studied
(Oliver et al, 1993)] may have reflected the fact that the first part
of the series was treated before there was any serious therapy
available for most of the time. Much of the consultation time was
spent 'brainwashing' the patient that spontaneous regression was a
realistic ifrare event. The reliefofpsychiatric stress in four out of
seven patients spontaneously regressing (Oliver, 1989) is witness
to the fact that neuroendrocrine factors might make a contribution
to response.
That selection is also a critical issue comes from the observation
that there is an inverse relationship between the distance travelled
for consultation and the frequency of response and survival in
patients treated in our renal cell cancer studies. This included a
patient who achieved an almost complete response after having
had to travel to London from Sydney to get drug supplies as the
drug is not available in Australia. This observation emphasizes
how much patient selection could play a role. The virtual absence
of response amongst renal cell cancer patients diagnosed in my
own district, which has one of the highest levels of poverty in
Europe, is the obverse of this observation. This is a particularly
telling observation when taken together with the fact that breast
cancer patients living in the same district have 20% worse survival
than those patients diagnosed in outer London suburban districts
(Oliver, 1997), whose renal cell cancerpatients when treated by us
have also had the highest frequency of response. That the same
difference in survival is observed when patients from these
extremes areas of residence are operated on for breast cancer by
the same surgeons in my own hospital demonstrates that it is not
an effect of delayed diagnosis or incompetent surgeons. These
observations on the impact of poverty on cancer survival have
been supported by the results of Shrijvers et al (1995) who also
demonstrated that it was a factor even after correction for stage at
presentation. Although the precise explanation for these differ-
ences is not known, they may reflect differences in environmental
pollution. Alternatively, they may possibly reflect the effect of a
lifetime exposure to subclinical deficiency of vitamin A, which is
known to influence T-cell immune responses (Semba et al, 1993)
and be a factor in breast cancer development (Hunter et al, 1993),
and/or vitamin D deficiency, which is known to influence
macrophage function (Davies, 1995) and be a factor in develop-
ment ofbreast and prostate cancer (Clark et al, 1996).
It is against this background that one must view the randomized
trial reported in this issue. This compares survival of63 metastatic
renal cell cancer patients receiving tamoxifen only vs 65 patients
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Table 1 Overview of cytokine phase 2 studies in metastatic renal cell
cancer (Horoszewicz and Murphy, 1989; Jeal and Goa, 1997)
No. of cases CR (%) PR (%) OR (%)
Interferon alpha alone 1100 2 14 16
IL-2 alone bolus 404 6 10 16
IL-2 alone c.i. 444 4 11 15
IL-2 alone s.c. 146 3 21 24
IL-2 + a-IFN i.v. 121 7 18 25
IL-2 + a-IFN s.c. 513 6 15 21
CR, complete response; PR, partial response; OR, no response.
receiving tamoxifen plus interleukin 2/alpha interferon for 6 weeks
followed by maintenance treatment for5 days every 4 weeks forup
to 12 months (Henriksson et al, 1998). This relatively small trial
failed to show any significant survival benefit inthis predominantly
poor-risk population, despite a 3% complete response in the control
arm and an 8% complete response inthe treatment arm. This obser-
vation, taken with the three negative cytokine trials (Gleave et al,
1997; Negrier et al, 1997; Pizzocaro et al, 1997) reported at ASCO
this year, raises the question as to whether there is anyjustification
for further trials. More specifically, is there anyjustification for the
proposed MRC/EORTC trial about to be launched comparing
nothing vs IL-2/alpha interferon/5-FU, particularly as one of the
negative trials reported at ASCO compared IL-2/alpha interferon+
5-FU in metastatic disease (Negrier et al, 1997). The answer must
be a resounding yes, and it could be said that there is a case for the
drug companies involved to almost feel a moral obligation to
encourage recruitment, given the continued ongoing scepticism
about cytokine therapy. Two positive trials, the first involving 425
patients comparing interferon alone, interleukin 2 alone and the
combination (Negrier et al, 1996) and the second comparing
tamoxifen vs IL-2/alpha interferon/5-FU inpatients with metastatic
disease (Atzpodien et al, 1997) when progression-free survival was
13 months in 41 patients in the experimental arm and 4 months for
37 patients in the tamoxifen arm (P<0.01) are the strongest data to
support the need forthis trial. Easy access to ultrasound, leading to
early diagnosis of renal tumours, and more frequent treatment of
patients at a stage when they only have small-volume lung metas-
tases with a high chance ofresponse (Lopez Hanninen et al, 1996)
are factors possibly explaining why the German data have for so
long been felt to be so different from what can be achieved in other
countries. This has been particularly so in the UK where most GPs
have to wait 1-3 months for such a procedure to be performed and
the response rate to the Atzpodian regimen has been half that seen
in Germany (Joffe et al, 1996). The new MRC/EORTC trial is an
adjuvant study that focuses on high-risk patients with vascular,
lymphatic or local invasion (T3/T4) in complete remission after
surgery. With evidence from the success of BCG in superficial
bladder cancer but not advanced disease suggesting that immune
response is more relevant at an early stage in the clonal evolution of
cancer, the proposed trial gives the maximum opportunity for
success.
However, even if this trial does succeed, as the paper of
Henriksson et al (1998) indicates, there is a need for new
approaches to working out dosages and duration oftreatment with
biological agents that have bell-shaped dose-response curves.
Even for alpha interferon 20 years after it was first used, it is far
from clear what is the optimum dose (Horoszewicz and Murphy,
1989). There has been some attempt to investigate this using in
vitro studies on bladder cancer cell lines. These have suggested
that beneficial alterations from cytokine treatment may only be
detectable on 20% oftumours because 20% have absent HLA that
cannot be induced and 60% had maximally expressed HLA that
could not be up-regulated and only 20% showed up-regulation in
response to interferon (Nouri et al, 1994). Before one could
consider such an approach for use clinically, it would be necessary
to develop a technique that could give an early result on fresh
tumour samples. Had this been possible in Henriksson's trial, the
exclusion of 80% of the cases and assumption that patients with
complete responses have an 80% chance ofdurable survival would
mean that the five complete responders in the IL-2/alpha inter-
feron arm compared with the two in the tamoxifen arm would have
translated into a 31% vs 12% 'cure,' which is nearly as good as the
difference between bleomycin velbe and single-agent chemo-
therapy in testis cancer.
Although ideal in theory, developing and validating treatment
response prediction assays would require substantive investment.
Developing better approaches to producing more active combina-
tion therapy is more likely to be a better way forward. With the
recently completed MRC trial of single-agent alpha interferon vs
medroxyprogestereone acetate (Fayers et al, 1994) stopped and
now undergoing detailed analysis after recruiting 365 patients in 5
years, there is an opportunity to examine the issue as to whether
two or three drugs are better than one. A first step forward might
be to confirm in a large randomized trial whether the observations
in the original data of Atzpodien are correct (Lopez Hanninen et
al, 1996), i.e. that in good and intermediate prognosis patients
there is a 15% benefit from adding 5-FU, while at the same time
doing a dose escalation study to confirm the literature overview
data (Jeal and Goa, 1997) (see Table 1) that going from single-
agent interleukin 2 or interferon to the two-drug combination of
IL-2/alpha interferon is associated with a 10% improvement in all
comers (Oliver, 1994). Setting up a large-scale pan-European trial
with a 2 x 2 design aimed to recruit 1000 patients in 5 years to
examine two doses ofinterferon ± interleukin 2 as one randomiza-
tion and ± 5-FU as the second randomization in patients with
metastatic renal cell cancer would provide really important infor-
mation that would establish beyond doubt the place of biotherapy
in this disease. Interest in this would be enhanced if it focused on
incorporating continuous infusion 5-FU rather than bolus, as used
by Atzpodien, as it has been shown to be better than bolus treat-
ment in stomach cancer. Restricting entry to good- and inter-
mediate-risk patients would leave the poor-risk patients for studies
ofnew agents.
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